CryoCath Presents at Prestigious Heart Rhythm Socie...( http://www MONTREAL Ma...),Health

http://www.cryocath.com Toronto Stock Exchange Symbol: CYT

MONTREAL, May 20 /PRNewswire-FirstCall/ - CryoCath(R) Technologies Inc., the global leader in cryotherapy products to treat cardiac arrhythmias, is pleased to report on its participation in Heart Rhythm 2008, the most prominent and comprehensive educational event on heart rhythm disorders. The event was held from May 14 to 17 at the Moscone Convention Center in San Francisco. This year, the meeting attracted a record-breaking 13,600 attendees and provided 250 educational opportunities in multiple formats. The world's leading electrophysiologists presented a broad range of heart rhythm topics.

CryoCath marked its presence at this prestigious gathering with 12 poster presentations and 10 well-attended oral presentations. For the most part, these presentations focused on the Arctic Front(R) cryoballoon system for pulmonary-vein isolation in the treatment of paroxysmal atrial fibrillation. Other presentations dealt with CryoCath's family of focal catheters for the treatment of a range of arrhythmias.

CryoCath's presence at Heart Rhythm 2008 provided the company with an excellent opportunity to further familiarize physicians with the growing body of evidence in favour of the cryoballoon approach in the treatment of AF. This included the consistent, positive results from multiple centres reported at the most recent Annual Meeting of the German Cardiac Society in Mannheim in March 2008.

A continuing area of discussion among electrophysiologists throughout the Heart Rhythm meeting was the possibility of injury and potentially fatal esophageal fistula due to ablation. Specifically, two presentations focused on this problem. As reported by Dr. Hiroshi Nakagawa, an animal study found that heat-based ablations can cause progressive ulceration of the esophagus, leading to esophagitis and fistula. In contrast, further study on t
'/>"/>